Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s share price traded up 3.8% on Tuesday . The company traded as high as $10.74 and last traded at $10.74. 1,695 shares changed hands during trading, a decline of 99% from the average session volume of 179,681 shares. The stock had previously closed at $10.35.
Analyst Ratings Changes
A number of equities research analysts recently commented on ALMS shares. Morgan Stanley began coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an "overweight" rating and a $36.00 price target on the stock. Guggenheim assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set a "buy" rating and a $32.00 price target on the stock. Leerink Partnrs raised Alumis to a "strong-buy" rating in a report on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a report on Monday, August 19th. Finally, Leerink Partners started coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an "outperform" rating and a $29.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Alumis presently has an average rating of "Buy" and an average price target of $27.50.
Read Our Latest Research Report on ALMS
Alumis Price Performance
The company's 50 day simple moving average is $11.90.
Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, equities analysts expect that Alumis Inc. will post -6.86 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ALMS. Towerview LLC purchased a new stake in shares of Alumis in the second quarter worth $4,123,000. SR One Capital Management LP purchased a new stake in shares of Alumis in the 2nd quarter valued at about $26,067,000. Ally Bridge Group NY LLC purchased a new stake in shares of Alumis in the 2nd quarter valued at about $8,229,000. Yu Fan bought a new stake in shares of Alumis during the 2nd quarter valued at about $10,502,000. Finally, Millennium Management LLC purchased a new position in shares of Alumis during the second quarter worth about $3,376,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
